Log in

NASDAQ:APTO - Aptose Biosciences Stock Price, Forecast & News

$7.70
-0.03 (-0.39 %)
(As of 02/28/2020 04:46 AM ET)
Today's Range
$6.87
Now: $7.70
$7.90
50-Day Range
$5.63
MA: $6.99
$9.00
52-Week Range
$1.57
Now: $7.70
$9.25
Volume1.61 million shs
Average Volume1.15 million shs
Market Capitalization$586.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.94
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APTO
CUSIPN/A
Phone64-7479-9828

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.37 per share

Profitability

Net Income$-28,870,000.00

Miscellaneous

EmployeesN/A
Market Cap$586.05 million
Next Earnings Date3/10/2020 (Confirmed)
OptionableOptionable

Receive APTO News and Ratings via Email

Sign-up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.


Aptose Biosciences (NASDAQ:APTO) Frequently Asked Questions

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) posted its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.01. View Aptose Biosciences' Earnings History.

When is Aptose Biosciences' next earnings date?

Aptose Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Aptose Biosciences.

How can I listen to Aptose Biosciences' earnings call?

Aptose Biosciences will be holding an earnings conference call on Tuesday, March 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for APTO?

5 brokerages have issued 1-year price targets for Aptose Biosciences' stock. Their forecasts range from $6.00 to $16.00. On average, they expect Aptose Biosciences' stock price to reach $10.25 in the next year. This suggests a possible upside of 33.1% from the stock's current price. View Analyst Price Targets for Aptose Biosciences.

What is the consensus analysts' recommendation for Aptose Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptose Biosciences.

Has Aptose Biosciences been receiving favorable news coverage?

Media coverage about APTO stock has been trending negative on Friday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aptose Biosciences earned a news impact score of -2.8 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Aptose Biosciences.

Are investors shorting Aptose Biosciences?

Aptose Biosciences saw a decrease in short interest during the month of February. As of February 14th, there was short interest totalling 361,300 shares, a decrease of 16.4% from the January 30th total of 432,200 shares. Based on an average trading volume of 1,240,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.5% of the shares of the stock are sold short. View Aptose Biosciences' Current Options Chain.

Who are some of Aptose Biosciences' key competitors?

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), Canopy Growth (CGC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Roku (ROKU) and SCYNEXIS (SCYX).

Who are Aptose Biosciences' key executives?

Aptose Biosciences' management team includes the folowing people:
  • Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)
  • Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)
  • Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell, Chief Medical Officer (Age 73)
  • Mr. Peter Murray, Director of Clinical Devel.

Who are Aptose Biosciences' major shareholders?

Aptose Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Ikarian Capital LLC (1.33%), Driehaus Capital Management LLC (1.28%), Point72 Asset Management L.P. (1.01%), P.A.W. Capital Corp (0.89%), Schonfeld Strategic Advisors LLC (0.84%) and Voss Capital LLC (0.40%). Company insiders that own Aptose Biosciences stock include Erich Platzer, Gregory K Chow and William G Rice. View Institutional Ownership Trends for Aptose Biosciences.

Which major investors are selling Aptose Biosciences stock?

APTO stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Man Group plc and Sanders Morris Harris LLC. View Insider Buying and Selling for Aptose Biosciences.

Which major investors are buying Aptose Biosciences stock?

APTO stock was bought by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Driehaus Capital Management LLC, Schonfeld Strategic Advisors LLC, Voss Capital LLC, P.A.W. Capital Corp, Monashee Investment Management LLC, Renaissance Technologies LLC and Goldman Sachs Group Inc.. Company insiders that have bought Aptose Biosciences stock in the last two years include Gregory K Chow and William G Rice. View Insider Buying and Selling for Aptose Biosciences.

How do I buy shares of Aptose Biosciences?

Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aptose Biosciences' stock price today?

One share of APTO stock can currently be purchased for approximately $7.70.

How big of a company is Aptose Biosciences?

Aptose Biosciences has a market capitalization of $586.05 million. The biotechnology company earns $-28,870,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. View Additional Information About Aptose Biosciences.

What is Aptose Biosciences' official website?

The official website for Aptose Biosciences is http://www.aptose.com/.

How can I contact Aptose Biosciences?

Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The biotechnology company can be reached via phone at 64-7479-9828 or via email at [email protected]


MarketBeat Community Rating for Aptose Biosciences (NASDAQ APTO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  319 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  584
MarketBeat's community ratings are surveys of what our community members think about Aptose Biosciences and other stocks. Vote "Outperform" if you believe APTO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: Closed-End Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel